

CRRT PRACTICE GUIDE

Sam Galvagno, DO, PhD

This is NOT meant to explain indications, physiology, etc. of CRRT! For details on that, contact Dr. Galvagno for some excellent reference articles (sgalvagno@anes.umm.edu). Also, see references below.

Typical Initial Settings:

- ✓ Blood flow: up to 180 mL/min
- ✓ Replacement: up to 4500 mL/hr
- ✓ Dialysate: up to 2500 mL/hr
- ✓ Ultrafiltration: up to 2000 mL/hr

Solutions

Primasate®- 5 L bag

Na⁺ 140, K⁺ 0, Cl⁻ 109.5, Ca²⁺ 3.5, Mg⁺ 1,
Lactate 3, HCO₃⁻ 32, glucose 0

Premixed Dialysate®-5 L bag

Na⁺ 140, K⁺ 2.0, Cl⁻ 117, Ca²⁺ 3.5, Mg⁺ 1.5,
Lactate 30, Glucose 100

Azotemia:

Increase your replacement fluid and/or dialysate flow rate

Hyponatremia:

Add 3% NaCl to your dialysate at 70 mL per 5 L bag

Hypernatremia:

Treat with peripheral D₅W (1L) or ½ NS as a background infusion

Potassium Management:

Serum K ⁺	What to add	1 L bag	5 L bag
> 5.5	0 mEq/L	None	None
4.5-5.5	3 mEq/L	7.5 mL	37.5 mL
< 4.5	4 mEq/L	10 mL	50 mL

pH Management:

Metabolic acidosis:

- ✓ Add NaHCO₃ in 100mL over 1 hour, IV, as needed
- ✓ Consider changing your replacement to D₅W (1L) plus 3 ampules of NaHCO₃

Metabolic alkalosis:

- ✓ Change your replacement solution to 0.9% NS with a sliding scale for potassium replacement

Calcium Management:

Hypercalcemia:

- ✓ Change to calcium free dialysate (bicarbonate based)
- ✓ Increase HCO₃ dialysate or replacement flow rate

Hypocalcemia:

- ✓ CaCl (10%) 10 ml/100mL 0.9% NS or D₅W over one hour, as needed
- ✓ Consider use of a premixed calcium infusion

Magnesium and Phosphate Management:

Hypomagnesemia:

- ✓ MgSO₃ (50%), 2 mL in 100 mL 0.9% NS or D₅W over one hour, as needed

Hypermagnesemia:

- ✓ Utilize same treatment as for hypercalcemia: Change to calcium free dialysate (bicarbonate based) and increase HCO₃ dialysate rate or replacement flow rate

Hypophosphatemia:

- ✓ Sodium phosphate (3 mmol/mL) 5 mL in 100 mL 0.9% NS IV over 2 hours, as needed, repeat as required for PO₃⁻ < 1.0 mg/dL

Hyperphosphatemia:

- ✓ Utilize same treatment as for hypercalcemia: Change to calcium free dialysate (bicarbonate based) and increase HCO₃ dialysate rate or replacement flow rate

Anticoagulation:

Heparin: 250-500 U/hr to start

For HIT, use argatroban, 0.5-1.0 mg/hr
Or citrate regional anticoagulation

Sample argatroban protocol:

1. Call hematology for approval / advice
2. 0.5-5 mL/hr; use lower dose (15 mcg/kg/hr) if in liver failure
3. Check aPTT every 12 hours

A few key CRRT papers:

1. Bellomo et al, NEJM 2009; 361(17): 1627-38.
2. Faber & Klein. Nursing Crit Care 2009; 14(4): 207-212.
3. Ghossein C, et al. International Anes clin 2009; 47(1): 15-24.
4. Stefan J. Chest 2007; 132: 1379-1388.
5. Thadhani R, et al. NEJM 1996; 334(22): 1448-1459.
6. VA/NIH trial. NEJM 2008; 359(1): 7-20.
7. Vissonneau C, et al. Lancet 2006; 379-85.
8. Tolwani, A. CRRT for AKI. NEJM 2012; 367: 2505-14.

Continuous Renal Replacement Therapy (CRRT) "Cheat Sheet"

Indications for renal replacement

Traditional	Other
A acidosis	Rhabdomyolysis
E electrolyte abnormalities	Sepsis
I intoxication	
O fluid overload	
U uremia	

Types of CRRT


- SCUF** - Slow continuous ultrafiltration (removal 1-4 mL/min or 3-6 g/day of urea). No replacement fluid.
- CVVH** - Continuous veno-veno hemofiltration (greater than 1L/hr ultrafiltrate production). Requires replacement fluid.
- CVVHD** - Continuous veno-veno hemodialysis (24-30 g/day urea clearance). Requires dialysate.
- CVVHDF** - Continuous veno-veno hemodiafiltration (36-38 g/day urea clearance). Requires dialysate and replacement fluid.

Definitions

- Ultrafiltrate (UF)** - Fluid collected in the bag distal to the hemofilter.
- Dialysate** - Fluid instilled into filter counter-current to flow of the ultrafiltrate.
- Effluent** = UF + dialysate
- Substitution/Replacement fluid** - Fluid instilled pre or post-filter to replace ultrafiltrate volume.
- Sieving coefficient (Sc)** - Ability of substance to pass through filter (Sc=1 passes freely; Sc=0 unable to pass).
- "Solute drag"** - Free circulating, unbound solutes carried with water during ultrafiltration. Solutes bound to red blood cells or proteins are NOT cleared.
- Qb** - Blood flow rate (typically 150-300 mL/min).
- QD** - Dialysate flow rate (typically 1-3 L/hr).

Filtration - convective clearance

occurs when water driven by hydrostatic or osmotic force is pushed through a membrane. Solutes that can pass easily through the membrane pores are swept along with the water ("solute drag").



$$\text{Convective clearance (urea)} = \text{UF (urea)} \times \text{Quf}$$

Plasma (urea)


Clearance is dependent on **ultrafiltration production rate**

UF (urea) = ultrafiltrate urea concentration (mg/dL), Quf = ultrafiltration production rate (mL/min), Plasma (urea) = plasma urea concentration (mg/dL).

Concepts

Dialysis - diffusive clearance

occurs due to movement of solutes as the result of random molecular motion. If the solute molecule encounters a pore of sufficient size, the molecule will pass through the filter. Can occur in either direction.



$$\text{Diffusive clearance (urea)} = \text{Dialysate (urea)} \times \text{Qd}$$


Plasma (urea)

Clearance is dependent on **dialysate infusion rate**

Dialysate (urea) = exiting dialysate urea concentration (mg/dL), Qd = dialysate flow rate (mL/min), Plasma (urea) = plasma urea concentration (mg/dL).

D. Stein and M. McCann - updated 6/06

CRRT "Cheat Sheet" page 2



Comparison of Different CRRT Modalities

Modality	Urea Clearance (g/Day)	Replacement Fluid / Dialysate	Middle Molecular Clearance
SCUF	1 - 4	No / No	+
CVVH	22 - 24	Yes / No	++
CVVHD	24 - 30	No / Yes	-
CVVHDF	36 - 38	Yes / Yes	+++

Clearance Table


Molecular size	Small solutes (< 300D)	Middle molecules (500-50,000D)	Low molecular weight proteins (5,000-50,000D)	Large proteins (> 50,000D)
Substances	Urea, creatinine, amino acids	Myoglobin, B12, vancomycin	Inflammatory mediators	Albumin
Clearance mechanism	Convection / Diffusion	Convection	Convection +/- adsorption	Convection

Anticoagulation Options

Type	Initiation	Monitor	Contraindications / Cautions
Heparin		Pre and post filter PTT	TBI, SCI, coagulopathy, HIT
Tri-Sodium Citrate		Pre and post-filter Ca ⁺⁺	Hypertremia, alkalosis, hypocalcemia

Initiation of CRRT

Select modality based on indication and goals of clearance/volume removal.



References:
Shillinglaw and Reynolds. Continuous renal replacement therapy and ultrafiltration. In: Complications in Trauma and Critical Care. WB Saunders 1996. Chapter 18.
Mann. Continuous renal replacement therapies: an update. Am J Kid Dis. 1998;32:185-207.
Ronco, Bellomo, and Ricci. Continuous renal replacement therapy in critically ill patients. Nephrol Dial Transplant. 2001;16:367-72.
Ronco, Ronco, Bachion, et al. Solute removal during continuous renal replacement therapy in critically ill patients: convection versus diffusion. Critical Care. 2006;10:R67.

D. Stein and M. McCann - updated 6/06